Cocrystal Pharma Q2 2024 Earnings Report
Key Takeaways
Cocrystal Pharma reported a net loss of $5.3 million, or $0.54 per share, for the second quarter of 2024. The company's R&D expenses increased due to the advancement of CC-42344 and CDI-988 into clinical studies. They expect their cash to be sufficient to advance planned development programs through the coming 12 months.
Phase 2a study with PB2 inhibitor CC-42344 topline results expected, including initial indication of virology in humans infected with influenza A virus.
Plan to file an Investigational New Drug (IND) application in 2025 to conduct next study in the U.S. for CC-42344.
Preparing to initiate a Phase 1 study in healthy volunteers to evaluate inhaled CC-42344 as a potential prophylactic and therapeutic for influenza A.
Preparations underway to begin the multiple-ascending dose portion of the first-in-human study with pan-norovirus/pan-coronavirus oral protease inhibitor CDI-988.
Cocrystal Pharma
Cocrystal Pharma
Forward Guidance
Cocrystal Pharma expects its cash to be sufficient to advance planned development programs through the coming 12 months.